Literature DB >> 24658838

Influence of natural killer cells and perforin‑mediated cytolysis on the development of chemically induced lung cancer in A/J mice.

Manuela Frese-Schaper, Andreas Keil, Hideo Yagita, Selina Katja Steiner, Werner Falk, Ralph Alexander Schmid, Steffen Frese.   

Abstract

One alternative approach for the treatment of lung cancer might be the activation of the immune system using vaccination strategies. However, most of clinical vaccination trials for lung cancer did not reach their primary end points, suggesting that lung cancer is of low immunogenicity. To provide additional experimental information about this important issue, we investigated which type of immune cells contributes to the protection from lung cancer development. Therefore, A/J mice induced for lung adenomas/ adenocarcinomas by the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) were depleted of CD4+ or CD8+ T cells, CD11b+ macrophages, Gr-1+ neutrophils and asialo GM1+ natural killer (NK) cells. Subsequent analysis of tumour growth showed an increase in tumour number only in mice depleted of NK cells. Further asking by which mechanism NK cells suppressed tumour development, we neutralized several death ligands of the tumour necrosis factor (TNF) family known to be involved in NK cell-mediated cytotoxicity. However neither depletion of TNF-α, TNF-related apoptosis-inducing ligand, TNF-like weak inducer of apoptosis or FasL alone nor in combination induced an augmentation of tumour burden. To show whether an alternative cell death pathway is involved, we next generated A/J mice deficient for perforin. After challenging with NNK, mice deficient for perforin showed an increase in tumour number and volume compared to wild-type A/J mice. In summary, our data suggest that NK cells and perforin-mediated cytolysis are critically involved in the protection from lung cancer giving promise for further immunotherapeutic strategies for this disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24658838     DOI: 10.1007/s00262-014-1535-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  5 in total

1.  Immune-enhancing effects of gamma-irradiated sericin.

Authors:  In-Bong Song; Hye-Ju Han; Jungkee Kwon
Journal:  Food Sci Biotechnol       Date:  2020-02-10       Impact factor: 2.391

2.  Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer.

Authors:  Lei Shi; Kang Li; Yizhan Guo; Anirban Banerjee; Qing Wang; Ulrike M Lorenz; Mahmut Parlak; Lucy C Sullivan; Oscar Okwudiri Onyema; Saeed Arefanian; Edward B Stelow; David L Brautigan; Timothy N J Bullock; Michael G Brown; Alexander Sasha Krupnick
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-31       Impact factor: 11.205

3.  NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells.

Authors:  Daniela Schilling; Annett Kühnel; Fabian Tetzlaff; Sarah Konrad; Gabriele Multhoff
Journal:  Cancer Immunol Immunother       Date:  2015-02-18       Impact factor: 6.968

4.  Deficiency of the adaptor protein SLy1 results in a natural killer cell ribosomopathy affecting tumor clearance.

Authors:  Saeed Arefanian; Daniel Schäll; Stephanie Chang; Reza Ghasemi; Ryuji Higashikubo; Alex Zheleznyak; Yizhan Guo; Jinsheng Yu; Hosseinali Asgharian; Wenjun Li; Andrew E Gelman; Daniel Kreisel; Anthony R French; Hani Zaher; Beatrice Plougastel-Douglas; Leonard Maggi; Wayne Yokoyama; Sandra Beer-Hammer; Alexander S Krupnick
Journal:  Oncoimmunology       Date:  2016-09-27       Impact factor: 8.110

5.  Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.

Authors:  Reza Ghasemi; Eric Lazear; Xiaoli Wang; Saeed Arefanian; Alexander Zheleznyak; Beatriz M Carreno; Ryuji Higashikubo; Andrew E Gelman; Daniel Kreisel; Daved H Fremont; Alexander Sasha Krupnick
Journal:  Nat Commun       Date:  2016-09-21       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.